308 related articles for article (PubMed ID: 31045745)
1. 18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy.
Evangelista L; Cuppari L; Menis J; Bonanno L; Reccia P; Frega S; Pasello G
Nucl Med Commun; 2019 Aug; 40(8):802-807. PubMed ID: 31045745
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
Zhu X; Liao C; Penney BC; Li F; Ferguson MK; Simon CA; Wu T; Liu H; Pu Y
Nucl Med Commun; 2017 Feb; 38(2):185-192. PubMed ID: 27922540
[TBL] [Abstract][Full Text] [Related]
3. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.
Zhang H; Wroblewski K; Appelbaum D; Pu Y
Int J Comput Assist Radiol Surg; 2013 Mar; 8(2):181-91. PubMed ID: 22644386
[TBL] [Abstract][Full Text] [Related]
4. Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.
Sharma A; Mohan A; Bhalla AS; Vishnubhatla S; Pandey AK; Bal CS; Kumar R
Nucl Med Commun; 2017 Oct; 38(10):858-867. PubMed ID: 28817456
[TBL] [Abstract][Full Text] [Related]
5. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
[TBL] [Abstract][Full Text] [Related]
6. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
7. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
[TBL] [Abstract][Full Text] [Related]
8. 18 F-FDG PET/CT for evaluation of metastases in nonsmall cell lung cancer on the efficacy of immunotherapy.
Feng Y; Wang P; Chen Y; Dai W
Nucl Med Commun; 2023 Oct; 44(10):900-909. PubMed ID: 37503694
[TBL] [Abstract][Full Text] [Related]
9. Metabolic activity by
Kaira K; Higuchi T; Naruse I; Arisaka Y; Tokue A; Altan B; Suda S; Mogi A; Shimizu K; Sunaga N; Hisada T; Kitano S; Obinata H; Yokobori T; Mori K; Nishiyama M; Tsushima Y; Asao T
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):56-66. PubMed ID: 28828507
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA
J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
[TBL] [Abstract][Full Text] [Related]
11. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of semiquantitative 18F-fluorodeoxyglucose PET/computed tomography in patients with advanced lung cancer for interim treatment evaluation of combining immunotherapy and chemotherapy.
Ke L; Wu L; Yu J; Meng X
Nucl Med Commun; 2021 Sep; 42(9):1017-1023. PubMed ID: 33899782
[TBL] [Abstract][Full Text] [Related]
14.
Takada K; Toyokawa G; Yoneshima Y; Tanaka K; Okamoto I; Shimokawa M; Wakasu S; Haro A; Osoegawa A; Tagawa T; Oda Y; Nakanishi Y; Mori M
Sci Rep; 2019 Sep; 9(1):13362. PubMed ID: 31527660
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
17.
Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y
Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer.
Seban RD; Assie JB; Giroux-Leprieur E; Massiani MA; Soussan M; Bonardel G; Chouaid C; Playe M; Goldfarb L; Duchemann B; Girard N; Champion L
Ann Nucl Med; 2020 Dec; 34(12):968-974. PubMed ID: 33070295
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of baseline metabolic tumor burden on
Shang J; You H; Dong C; Li Y; Cheng Y; Tang Y; Guo B; Gong J; Ling X; Xu H
Front Oncol; 2022; 12():1029684. PubMed ID: 36387169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
